There were 127 patients in PRFA group patients with LC and 50 patients in SR group patients with LC, respectively. The 1-, 3-and 5-year overall survival rates after PRFA and SR were 94.2%, 75.8% and 56.4%, respectively in the PRFA group with LC and 100%, 78.0% and 67.8%, respectively in the SR group with LC. (Figure 4 ) The corresponding recurrence free survival rates at 1, 3 and 5 years after PRFA and SR were 86.0%, 35.0% and 14.8%, respectively in the PRFA group with LC and 79.5%, 39.3% and 23.8%, respectively in the SR group with LC. (Figure 5 ) In terms of overall survival (P = 0.521) and recurrence free survival (P = 0.669), there were no significant differences between these two groups.